Naltrexone SR/bupropion SR (Contrave): A new approach to weight loss in obese adults

P and T

Volumn 36, Issue 5, 2011, Pages 255-362

  Ornellas, Tehane ^a   Chavez, Benjamin ^b  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 3 METHOXY 6BETA NALTREXOL; 2 HYDROXY 3 METHYLNALTREXONE; AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; DOPAMINE UPTAKE INHIBITOR; ERYTHROHYDROBUPROPION; MORPHINE DERIVATIVE; NALOXONE; NALTREXOL; NALTREXONE; OXYMORPHONE; PLACEBO; PROOPIOMELANOCORTIN; THREOHYDROBUPROPION; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR MODIFICATION; BODY MASS; BODY WEIGHT; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FIRST PASS EFFECT; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOTENSION; LOW CALORY DIET; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OBESITY; PHYSICAL CHEMISTRY; RISK FACTOR; SUSTAINED DRUG RELEASE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 79958282647     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Centers for Disease Control and Prevention (CDC). Adult obesity: Obesity rises among adults, August 3, 2010. Available at: www.cdc.gov/vitalsigns/AdultObesity. Accessed January 9, 2011.
2. Centers for Disease Control and Prevention (CDC). Overweight and obesity, data and statistics. October 8, 2010. Available at: www.cdc.gov/obesity/data/index.html. Accessed January 9, 2011.
3. Centers for Disease Control and Prevention (CDC). FastStats: Obesity and overweight, June 18, 2010. Available at: www.cdc.gov/nchs/fastats/overwt.htm. Accessed January 9, 2011.
4. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010;363:2211-2219.
5. DailyMed. National Library of Medicine, January 2010. Naltrexone. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=37807. Bupropion SR: Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=31150. Accessed January 10, 2011.
6. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376(9741):595-605.
7. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD Trial. Obesity (Silver Spring) 2011;19(1):110-120.
8. Naltrexone/bupropion. Adis Online. com, R&D Profile. Drugs RD 2010;10(1):25-32.
9. Greenway FL, Dunayevich E, Tollefson G, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009;94(12):4898-4906.
10. FDA issues complete response to New Drug Application for Contrave for the management of obesity. Orexigen Therapeutics: San Diego/Osaka; February 1, 2011. Available at: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irolnewsArticle&ID=1522207&highlight=. Accessed February 2, 2011.
11. Pollack A. FDA declines to approve diet drug. The New York Times, February 1, 2011. Available at: www.nytimes.com/2011/02/02/business/02drug.html?_r=1&ref=orexigentherapeuticsinc. Accessed April 25, 2011.
12. Pollack A. No FDA approval for new diet pill. The New York Times, October 23, 2010. Available at: www.nytimes.com/2010/10/24/business/24obesity.html. Accessed February 3, 2011.
13. Pollack A. FDA rejects Qnexa, a third weight-loss drug. The New York Times, October 28, 2010. Available at: www.nytimes.com/2010/10/29/health/policy/29drug.html?_r=1&scp=1&sq=qnexa&st=Search. Accessed February 3, 2011.
14. Joelving F. Roche's diet drug tied to kidney damage. Reuters, April 12, 2011. Available at: http://us.mobile.reuters.com/article/healthNews/idUSTRE73B7SZ20110412?irpc=932. Accessed April 20, 2011.